Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY-J: Dostarlimab + Carboplatin-paclitaxel in Japanese Patients With Advanced or Recurrent Endometrial Cancer
NCT06317311Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab in endometrial cancer (EC), sponsored by GSK. Started May 2024; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06317311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06317311.